{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:16Z","timestamp":1791262336557,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110460","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:38:22Z","timestamp":1788244702000},"page":"110460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine\/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors"],"prefix":"10.1016","volume":"182","author":[{"given":"Naglaa M.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizk E.","family":"Khidre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Khidre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"El-Adl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura S.","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110460_bb0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2026.110460_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114912","article-title":"Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4 (3H)-ones and sulfachloropyridazine","volume":"245","author":"Zahran","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110460_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drup.2009.03.001","article-title":"Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy","volume":"12","author":"Dent","year":"2009","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2026.110460_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-642-59953-8_4","article-title":"Structure and function of vascular endothelial growth factor receptor-1 and-2","author":"Shibuya","year":"1999","journal-title":"Vascular growth factors and angiogenesis"},{"key":"10.1016\/j.bioorg.2026.110460_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118679","article-title":"Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR\/Aurora kinase inhibitors against hepatocellular and breast carcinomas","volume":"192","author":"Anwer","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110460_bb0035","first-page":"50","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bioorg.2026.110460_bb0040","first-page":"37","article-title":"Vascular endothelial growth factor receptors: expression and function in solid tumors","volume":"2","author":"Wey","year":"2004","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110460_bb0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14756366.2017.1334650","article-title":"VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo [g] quinazolin bearing benzenesulfonamide moiety","volume":"32","author":"Ghorab","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.yexcr.2005.11.008","article-title":"VEGF function in vascular pathogenesis","volume":"312","author":"Ng","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2026.110460_bb0055","first-page":"222","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110460_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0163-7258(98)00044-8","article-title":"Strategies toward the design of novel and selective protein tyrosine kinase inhibitors","volume":"82","author":"Traxler","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110460_bb0065","article-title":"Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110460_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020226","article-title":"Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2, 4-diones bearing sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPAR\u03b3 agonists","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110460_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4161\/cbt.4.7.2014","article-title":"PPAR\u03b3 as a therapeutic target for tumor angiogenesis and metastasis","volume":"4","author":"Panigraphy","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2026.110460_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110460_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1517\/13543776.2014.871527","article-title":"Epidermal growth factor receptor inhibitors: a patent review (2010\u2013present)","volume":"24","author":"Li","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110460_bb0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/106689690501300202","article-title":"Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma","volume":"13","author":"Raspollini","year":"2005","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bioorg.2026.110460_bb0100","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14728222.2017.1371137","article-title":"VEGF as a potential target in lung cancer","volume":"21","author":"Frezzetti","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.110460_bb0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"50","key":"10.1016\/j.bioorg.2026.110460_bb0110","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008704","article-title":"Treatment of medullary thyroid carcinoma with apatinib","volume":"96","author":"Cai","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"10.1016\/j.bioorg.2026.110460_bb0115","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1016\/j.bmc.2010.05.063","article-title":"The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec\u00ae, Nexavar\u00ae, and BIRB-796","volume":"18","author":"Dietrich","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0120","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110460_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104222","article-title":"Selective VEGFR-2 inhibitors: synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling","volume":"103","author":"AbdelHaleem","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100085","article-title":"Pyridine-derived VEGFR-2 inhibitors: rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking","volume":"354","author":"Saleh","year":"2021","journal-title":"Arch. Pharm."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110460_bb0135","doi-asserted-by":"crossref","first-page":"12184","DOI":"10.1039\/D3RA00416C","article-title":"Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies","volume":"13","author":"Al-Muntaser","year":"2023","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110460_bb0140","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1039\/D5RA04838A","article-title":"Thiazole\u2013driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications","volume":"16","author":"Dsouza","year":"2026","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110460_bb0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/molecules24040682","article-title":"Hum, synthesis, characterization, and biological activity of a novel series of benzo [4, 5] imidazo [2, 1-b] thiazole derivatives as potential epidermal growth factor receptor inhibitors","volume":"24","author":"Deng","year":"2019","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.bioorg.2026.110460_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115657","article-title":"Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors","volume":"28","author":"Srour","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110460_bb0155","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/molecules28020689","article-title":"Synthesis and molecular docking of some novel 3-thiazolyl-coumarins as inhibitors of VEGFR-2 kinase","volume":"28","author":"Abolibda","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110460_bb0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bioorg.2016.06.006","article-title":"5-Benzylidene-2,4-thiazolidenedione derivatives: design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2","volume":"67","author":"Bhanushali","year":"2016","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110460_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/sym14091814","article-title":"Design, synthesis and cytotoxicity screening of new thiazole derivatives as potential anticancer agents through VEGFR-2 inhibition","volume":"14","author":"Al-Warhi","year":"2022","journal-title":"Symmetry"},{"key":"10.1016\/j.bioorg.2026.110460_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108023","article-title":"Exploring a novel thiazole derivatives hybrid with fluorinated-indenoquinoxaline as dual inhibitors targeting VEGFR2\/AKT and apoptosis inducers against hepatocellular carcinoma with docking simulation","volume":"154","author":"Abusaif","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109164","article-title":"Chitosan\/polyacrylic acid nanogel-mediated delivery system for cancer treatment: design, synthesis, ADMET, docking of thiazole derivatives as dual inhibitors of VEGFR-2 and EGFRT790M","volume":"166","author":"Abdelgawad","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100201","article-title":"Phthalazine-based VEGFR-2 inhibitors: rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations","author":"Khedr","year":"2021","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110460_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700240","article-title":"Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors","volume":"350","author":"El-Helby","year":"2017","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110460_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106791","article-title":"New quinazoline sulfonamide derivatives as potential anticancer agents: identifying a promising hit with dual EGFR\/VEGFR-2 inhibitory and radiosensitizing activity","volume":"140","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104218","article-title":"Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents","volume":"104","author":"El-Zahabi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104350","article-title":"Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors","volume":"104","author":"Saleh","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135164","article-title":"Immunomodulatory quinazoline-based thalidomide analogs: design, synthesis, apoptosis and anticancer evaluations","volume":"1281","author":"Abdallah","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110460_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300137","article-title":"Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment","author":"Hanafy","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110460_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136047","article-title":"Pyrazolo[3,4-d]pyrimidine derivatives as EGFRT790M and VEGFR-2 dual TK inhibitors: design, synthesis, molecular docking, ADMET profile and anticancer evaluations","volume":"1291","author":"Adel","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110460_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300097","article-title":"Novel promising benzoxazole\/benzothiazole-derived immunomodulatory agents: design, synthesis, anticancer evaluation, and in silico ADMET analysis","author":"Elkady","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110460_bb0225","first-page":"1","article-title":"Design, synthesis, anticancer evaluation, in silico docking and ADMET analysis of novel indole-based thalidomide analogs as promising immunomodulatory agents","author":"El-Zahabi","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110460_bb0230","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","article-title":"Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors","volume":"45","author":"Lee","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0235","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1016\/j.bmc.2015.08.010","article-title":"Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors","volume":"23","author":"Machado","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0240","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110460_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pr12061055","article-title":"Novel hydrazide hydrazone derivatives as antimicrobial agents: design, synthesis, and molecular dynamics","volume":"12","author":"Agili","year":"2024","journal-title":"Processes"},{"key":"10.1016\/j.bioorg.2026.110460_bb0250","article-title":"Novel nano-sized N-thiazolylpyridylamines targeting CDK2: design, divergent synthesis, conformational studies, and multifaceted in silico analysis Samir Bondocka,*","volume":"407","author":"Alabbada","year":"2025","journal-title":"Chem. Biol. Interact."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110460_bb0255","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.3390\/molecules27196368","article-title":"Synthesis, molecular docking study, and cytotoxicity evaluation of some novel 1,3,4-Thiadiazole as well as 1,3-thiazole derivatives bearing a pyridine moiety","volume":"27","author":"Abouzied","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110460_bb0260","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2017.06.041","article-title":"Hydrazinyl aryl thiazole based pyridine scaffolds: synthesis, structural characterization, in vitro \u03b1-glucosidase inhibitory activity, and in silico studies","volume":"138","author":"Ali","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0265","doi-asserted-by":"crossref","first-page":"31607","DOI":"10.1039\/D4RA06146B","article-title":"Design, synthesis and in vitro anti-proliferative evaluation of new pyridine-2,3-dihydrothiazole\/ thiazolidin-4-one hybrids as dual CDK2\/GSK3b kinase inhibitors","volume":"14","author":"Kassem","year":"2024","journal-title":"RSC Adv."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110460_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000068","article-title":"Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors","volume":"353","author":"El-Adl","year":"2020","journal-title":"Arch Pharm (Weinheim)."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110460_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200465","article-title":"Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: design, synthesis, ADMET, docking, and antiproliferative evaluations","volume":"356","author":"Aziz","year":"2023","journal-title":"Arch Pharm (Weinheim)."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110460_bb0280","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.1039\/D2RA01119K","article-title":"Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2\/EGFRT790M tyrosine kinase inhibitors","volume":"12","author":"Aziz","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110460_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102944","article-title":"Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR\/HER2 inhibitors and apoptosis inducers","volume":"88","author":"Elmetwally","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0290","first-page":"4827","article-title":"Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines","volume":"48","author":"Scudiero","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110460_bb0295","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2005.02.040","article-title":"Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics","volume":"43","author":"Huether","year":"2005","journal-title":"J. Hepatol."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.110460_bb0300","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.110460_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105186","article-title":"Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents","volume":"115","author":"Abd El-Sattar","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110460_bb0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ab.2006.05.006","article-title":"Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery","volume":"356","author":"Jia","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ml300327z","article-title":"Structure-based approach for the discovery of pyrrolo[3, 2-d]pyrimidine-based EGFR T790M\/L858R mutant inhibitors","volume":"4","author":"Sogabe","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110460_bb0320","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1242\/jcs.113.5.753","volume":"113","author":"Wang","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioorg.2026.110460_bb0325","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2026.110460_bb0330","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110460_bb0335","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110460_bb0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.110460_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/10ae05dc-90cb-46f1-aa2b-e63eb4a132e2","article-title":"Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations","volume":"8","author":"Beig","year":"2013","journal-title":"PLoS One"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600996X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600996X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:18:38Z","timestamp":1791260318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600996X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"alternative-id":["S004520682600996X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110460","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine\/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110460"}}